METHODS: This retrospective case-series recruited 44 eyes for glaucoma patients who were younger than 17 years and were treated with MP-CPC and followed for at least one year. Pre- and post-intervention intraocular pressure (IOP) was compared out to at least one year postoperatively. Success rates at 6 months and 1 year postoperatively were assessed. P < 0.05 was considered statistically significant.
RESULTS: There were 35 (79.5%) eyes with a history of glaucoma surgery. IOP decreased statistically significantly from a baseline of 32.7 (standard deviation:8.7 mmHg) to 23.2 (8.6) and 21.7 (7.9) mmHg at the 6 months and 1-year follow-up, respectively (P < 0.0001, all comparisons). Overall success was noted in 19 (47.5%) eyes at the 6 months follow-up, and 23 (53.5%) eyes at 1 year.
CONCLUSIONS: MP-CPC reduces IOP and the burden of medications in paediatric patients with glaucoma. Additionally, its safety profile favours the use of MP-CPC as an adjunctive modality for refractory glaucoma.
方法:该回顾性病例系列招募了44只年龄小于17岁的青光眼患者的眼睛,并接受了MP-CPC治疗,随访至少一年。将干预前后的眼内压(IOP)与术后至少一年进行比较。评估术后6个月和1年的成功率。P<0.05被认为具有统计学意义。
结果:有青光眼手术史的35只(79.5%)眼。在6个月和1年随访时,眼压从基线32.7(标准差:8.7mmHg)下降到23.2(8.6)和21.7(7.9)mmHg,分别(P<0.0001,所有比较)。在6个月的随访中,19只眼睛(47.5%)总体成功。1年时23只(53.5%)眼。
结论:MP-CPC可降低小儿青光眼患者的眼压和药物负担。此外,其安全性有利于MP-CPC作为难治性青光眼的辅助治疗方式.